Abstract
Curcumin, a natural polyphenolic compound present in turmeric, exhibited multiple pharmacological activities. Extensive studies in last two decade suggested that curcumin possesses anti-inflammatory, anticancer, antiviral, anti-amyloid, antiarthritic and antioxidant properties. The mechanism for these effects involves modulation of several signaling transduction pathways. Various clinical studies have suggested that curcumin might be a potential candidate for the prevention and/or treatment of a variety of colonic diseases such as ulcerative colitis, Crohn’s disease and colonic cancer. However, several evidences suggested the role of curcumin in multiple diseases, but the major challenge is to obtain optimum therapeutic levels of curcumin due to its low solubility and poor bioavailability. Improved absorption and cellular uptake of curcumin can be achieved through alteration in formulation properties and novel approaches in delivery systems. This review presents an overview of the background of curcumin, pharmacology, pharmacokinetics, clinical evidence in chemoprevention of bowel diseases and recent approaches to deliver curcumin for improved cellular uptake and bioavailability.
Keywords: Approaches, curcumin, clinical studies, colon cancer, inflammatory bowel disease, turmeric.
Current Drug Targets
Title:Curcumin: A Boon to Colonic Diseases
Volume: 14 Issue: 10
Author(s): Rashmi Sareen, Nitin Jain and Vinay Pandit
Affiliation:
Keywords: Approaches, curcumin, clinical studies, colon cancer, inflammatory bowel disease, turmeric.
Abstract: Curcumin, a natural polyphenolic compound present in turmeric, exhibited multiple pharmacological activities. Extensive studies in last two decade suggested that curcumin possesses anti-inflammatory, anticancer, antiviral, anti-amyloid, antiarthritic and antioxidant properties. The mechanism for these effects involves modulation of several signaling transduction pathways. Various clinical studies have suggested that curcumin might be a potential candidate for the prevention and/or treatment of a variety of colonic diseases such as ulcerative colitis, Crohn’s disease and colonic cancer. However, several evidences suggested the role of curcumin in multiple diseases, but the major challenge is to obtain optimum therapeutic levels of curcumin due to its low solubility and poor bioavailability. Improved absorption and cellular uptake of curcumin can be achieved through alteration in formulation properties and novel approaches in delivery systems. This review presents an overview of the background of curcumin, pharmacology, pharmacokinetics, clinical evidence in chemoprevention of bowel diseases and recent approaches to deliver curcumin for improved cellular uptake and bioavailability.
Export Options
About this article
Cite this article as:
Sareen Rashmi, Jain Nitin and Pandit Vinay, Curcumin: A Boon to Colonic Diseases, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990168
DOI https://dx.doi.org/10.2174/13894501113149990168 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Serum HSP90-Alpha and Oral Squamous Cell Carcinoma: A Prospective Biomarker
Protein & Peptide Letters Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Mechanisms Controlling Sensitivity to Platinum Complexes: Role of p53 and DNA Mismatch Repair
Current Cancer Drug Targets Proteasomal Inhibition: A Novel Pathway for Prevention of Atherosclerosis and Restenosis
Vascular Disease Prevention (Discontinued) Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Pharmacokinetics of CNT-based Drug Delivery Systems
Current Drug Metabolism Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets Novel Strategies for Effective Actinic Keratosis Treatment: A Review
Current Cancer Therapy Reviews Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry On the Origin of Epidermal Cancers
Current Molecular Medicine Gene Therapy to Overcome Drug Resistance in Cancer: Targeting Key Regulators of the Apoptotic Pathway
Current Gene Therapy Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs
Anti-Cancer Agents in Medicinal Chemistry Nutraceuticals for Promoting Longevity
Current Nutraceuticals MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA